Oral hypoglycemic drugs

Reading File

Now let me search the medical library for oral hypoglycemic drugs comprehensively.

Finding Sources

Katzung's Pharmacology is the primary source. Let me read the antidiabetic drugs section from Katzung and the Goldman-Cecil section simultaneously.

Reading File

The Katzung block wasn't the right section. Let me search specifically in Katzung for the diabetes/OHA chapter.

Finding Sources

Found the Katzung diabetes chapter. Let me read it along with a paragraphs search for key drug classes.

Reading File

Excellent - this is the Katzung diabetes chapter. The read started from ~3600 but the OHA section starts at 3847. Let me read from that point forward for comprehensive drug class coverage.

Reading File

This is very rich content. Let me read the next section continuing from where the truncation occurred to get full coverage of all drug classes.

Reading File

I got a lot of content from the Katzung chapter in the earlier large read (offset 3847, 300 lines) which was truncated. I have comprehensive data from the sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors sections in the truncated output. Let me now compile a comprehensive answer from all the content collected. I have enough information from the Katzung pharmacology textbook to provide a thorough, well-organized response.

Oral Hypoglycemic Drugs (Antidiabetic Agents)

Based on Katzung's Basic and Clinical Pharmacology, 16th Edition and Goldman-Cecil Medicine.

Overview

Oral hypoglycemic drugs (also called oral glucose-lowering agents) are used primarily in type 2 diabetes mellitus, where tissue insulin resistance and relative insulin deficiency coexist. They work through several distinct mechanisms: stimulating insulin secretion, improving insulin sensitivity, slowing carbohydrate absorption, or increasing renal glucose excretion.

Classification

1. Insulin Secretagogues

A. Sulfonylureas

Mechanism: Bind to the 140-kDa sulfonylurea receptor (SUR1) on pancreatic beta cells, which is associated with an ATP-sensitive K+ channel (K_ATP). Binding inhibits K+ efflux → membrane depolarization → voltage-gated Ca²+ channel opens → Ca²+ influx → release of preformed insulin.

Generations:

Generation	Drugs
1st	Tolbutamide, chlorpropamide, tolazamide, acetohexamide
2nd	Glibenclamide (glyburide), glipizide, glimepiride

Key pharmacology:

Metabolized by the liver; metabolites are excreted renally (and partly in bile for 2nd-generation)
2nd-generation drugs have much greater receptor affinity at lower doses → fewer drug interactions
Acetohexamide is unique: its metabolite is more active than the parent compound
Chlorpropamide has the longest half-life (~35 hours) and can cause SIADH (dilutional hyponatremia)

Adverse effects:

Hypoglycemia (most important; especially with chlorpropamide, glyburide)
Weight gain
Rare: skin rashes, hematologic toxicity (leukopenia, thrombocytopenia) in <0.1%
Disulfiram-like reaction with alcohol (especially chlorpropamide)
Drug interactions: sulfonamides, salicylates, clofibrate displace from plasma proteins → potentiate hypoglycemia

UKPDS: Found no excess cardiovascular mortality with sulfonylureas (unlike the flawed 1970 UGDP study).

B. Meglitinides (Non-Sulfonylurea Secretagogues)

Drugs: Repaglinide, nateglinide

Mechanism: Also bind to the sulfonylurea receptor (same K_ATP channel), but at a different binding site. They are rapid-acting and short-duration insulin releasers - taken with each meal to cover postprandial glucose spikes.

Key features:

Repaglinide: metabolized by liver (CYP3A4); safe in renal impairment
Nateglinide: phenylalanine derivative; even faster onset; less risk of hypoglycemia
Main advantage: flexibility - if a meal is skipped, the dose is omitted

Adverse effects: Hypoglycemia (less than sulfonylureas), weight gain

2. Insulin Sensitizers

A. Biguanides - Metformin

The most widely prescribed oral antidiabetic drug.

Mechanism:

Activates AMP-activated protein kinase (AMPK) via inhibition of complex I of the mitochondrial respiratory chain
Primary action: Reduces hepatic glucose output (suppresses gluconeogenesis and glycogenolysis)
Also improves peripheral glucose uptake in muscle
Does NOT cause hypoglycemia when used alone (no effect on insulin secretion)
Does NOT cause weight gain (weight-neutral to mild weight loss)

UKPDS benefit: Metformin reduced macrovascular events and mortality in overweight type 2 diabetic patients - a landmark finding.

Pharmacokinetics:

Not metabolized; excreted unchanged by kidneys
Plasma half-life ~2 hours; eliminated within 12 hours in normal renal function

Adverse effects:

GI effects: nausea, diarrhea, anorexia (most common - take with food to reduce)
Lactic acidosis: rare but potentially fatal; risk increases with renal impairment, hepatic failure, alcohol use, contrast media, or hypoxic states - contraindicated when eGFR <30 mL/min/1.73m²
Vitamin B12 malabsorption with long-term use
Metallic taste

Contraindications: Renal impairment (eGFR <30), hepatic failure, heart failure (unstable), alcoholism, contrast procedures (hold 48h before)

B. Thiazolidinediones (TZDs / "Glitazones")

Drugs: Pioglitazone, rosiglitazone (restricted use)

Mechanism: Bind to peroxisome proliferator-activated receptor gamma (PPAR-γ) in adipose, liver, and muscle → transcriptional regulation → enhanced insulin sensitivity at peripheral tissues and liver. Reduce free fatty acid levels, improve adipokine profile (↑ adiponectin, ↓ TNF-α).

Key features:

Full effect takes 6-12 weeks
Do NOT cause hypoglycemia alone
Pioglitazone improves lipid profile (↑ HDL, ↓ triglycerides); rosiglitazone raises LDL

Adverse effects:

Fluid retention / edema - major concern; can precipitate or worsen heart failure
Weight gain (fat redistribution - increases subcutaneous fat)
Bone loss / fractures (especially distal limb fractures in women)
Rosiglitazone: associated with increased MI risk → restricted/withdrawn in many countries
Pioglitazone: possible increased bladder cancer risk with long-term use

Contraindications: Heart failure (NYHA Class III-IV), active bladder cancer (pioglitazone), hepatic disease

3. Alpha-Glucosidase Inhibitors

Drugs: Acarbose, miglitol, voglibose

Mechanism: Competitively inhibit intestinal alpha-glucosidases (maltase, sucrase, glucoamylase) and pancreatic alpha-amylase → delays digestion and absorption of complex carbohydrates and disaccharides → blunts postprandial hyperglycemia.

Key features:

Act locally in the gut; minimal systemic absorption (acarbose); miglitol is absorbed
No hypoglycemia when used alone
Modest HbA1c reduction (~0.5-0.8%)
Must be taken with the first bite of each meal

Adverse effects:

Flatulence, bloating, diarrhea, abdominal cramps (very common; due to undigested CHO fermentation in colon)
Rarely: elevated liver transaminases (acarbose at high doses)
If hypoglycemia occurs while on these drugs (combined therapy), treat with glucose (dextrose), NOT sucrose - because sucrase is inhibited

Contraindications: Inflammatory bowel disease, intestinal obstruction, renal impairment (miglitol if eGFR <25)

4. DPP-4 Inhibitors ("Gliptins")

Drugs: Sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin

Mechanism: Inhibit dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades endogenous GLP-1 and GIP (incretin hormones) → ↑ incretin levels → glucose-dependent stimulation of insulin secretion + suppression of glucagon. Effects are glucose-dependent (only work when glucose is elevated).

Key features:

Weight neutral
Low hypoglycemia risk
Oral, once-daily dosing
Linagliptin is unique: excreted unchanged in bile; safe in renal impairment without dose adjustment

Adverse effects:

Nasopharyngitis, upper respiratory infections (class effect)
Rare: acute pancreatitis
Saxagliptin: associated with increased heart failure hospitalizations (FDA warning)
Rare: severe joint pain (arthralgia)

5. GLP-1 Receptor Agonists (Injectable - for completeness)

Drugs: Liraglutide, semaglutide (oral form available), exenatide, dulaglutide, albiglutide

Mechanism: Mimic GLP-1 → glucose-dependent insulin release, suppress glucagon, slow gastric emptying, promote satiety.

Key benefits:

Significant weight loss
Cardiovascular benefit: liraglutide and semaglutide reduce MACE (MI, stroke, CV death) - LEADER and SUSTAIN-6 trials
Semaglutide has an oral formulation (Rybelsus)

Adverse effects: Nausea, vomiting, pancreatitis, thyroid C-cell tumors (animal data - avoid in MEN2/medullary thyroid cancer)

6. SGLT-2 Inhibitors ("Gliflozins")

Drugs: Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin

Mechanism: Inhibit sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubule → block ~90% of glucose reabsorption → glucosuria (excrete ~60-80 g glucose/day in urine).

Key benefits (beyond glucose lowering):

Heart failure: Empagliflozin (EMPA-REG OUTCOME) and dapagliflozin (DAPA-HF) reduce mortality and HF hospitalizations - approved for HFrEF with or without diabetes
Renal protection: Slow progression of diabetic nephropathy
Weight loss (caloric loss via glucosuria)
Modest blood pressure reduction
Canagliflozin: reduces renal events in diabetic nephropathy (CREDENCE trial)

Adverse effects:

Genital mycotic infections (most common - due to glucosuria) - more in women
Urinary tract infections
Euglycemic diabetic ketoacidosis (rare but serious - can occur in type 1 or perioperatively)
Canagliflozin: increased lower limb amputations, bone fractures
Volume depletion / hypotension
Fournier's gangrene (necrotizing fasciitis of genitalia - rare)

Contraindicated in: eGFR <30 (glucose-lowering effect lost), recurrent UTI/genital infections

7. Other / Miscellaneous

Drug	Class	Mechanism	Notes
Pramlintide	Amylin analog	Slows gastric emptying, suppresses glucagon, promotes satiety	Injectable; used with insulin
Colesevelam	Bile acid sequestrant	Mechanism unclear	Modest HbA1c reduction; also lowers LDL
Bromocriptine	Dopamine agonist	Resets hypothalamic circadian clock; improves insulin sensitivity	Take within 2h of waking

Comparison Summary Table

Drug Class	Mechanism	Hypoglycemia Risk	Weight Effect	Key Advantage
Sulfonylureas	↑ Insulin secretion (K_ATP block)	Yes	Gain	Cheap, effective
Meglitinides	↑ Insulin secretion (prandial)	Low	Gain	Flexible dosing
Metformin	↓ Hepatic glucose output (AMPK)	No	Neutral/loss	1st line; CV benefit
TZDs	PPAR-γ agonist (↑ sensitivity)	No	Gain	Durable effect
Alpha-glucosidase inhibitors	Delay CHO absorption	No	Neutral	Postprandial control
DPP-4 inhibitors	↑ Incretin levels	No	Neutral	Well tolerated
GLP-1 agonists	GLP-1R stimulation	No	Loss	CV + weight benefit
SGLT-2 inhibitors	Glucosuria	No	Loss	HF + renal protection

First-Line and Combination Therapy

Metformin remains the cornerstone first-line agent (unless contraindicated)
GLP-1 agonists or SGLT-2 inhibitors are added when cardiovascular disease, heart failure, or chronic kidney disease is present (regardless of glycemic control)
Sulfonylureas are still widely used as second-line add-on therapy where cost matters
Insulin is added when oral agents are insufficient or in late-stage disease

Source: Katzung's Basic and Clinical Pharmacology, 16th Edition, Chapter 41; Goldman-Cecil Medicine

This is a shared conversation. Sign in to Orris to start your own chat.